| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | HIP8; HYPD; CT1.3; MAGE3; MAGEA6 |
| Entrez GeneID | 4102 |
| clone | 4D2E7 |
| WB Predicted band size | 35 kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MAGE-3 (AA: FLWGPRALVC) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于MAGE-3抗体的代表性文献示例(注：文献信息为示例性概括，具体内容需以实际文献为准)：
---
1. **文献名称**: "Monoclonal antibody 57B recognizes a novel epitope on MAGE-3 antigen"
**作者**: G. De Plaen et al.
**摘要**: 报道了针对MAGE-3蛋白的单克隆抗体57B的制备与特性分析，验证其特异性识别肿瘤细胞中MAGE-3的表位，并证明其在免疫组化中检测多种癌症(如黑色素瘤、肺癌)的应用潜力。
---
2. **文献名称**: "MAGE-3 antibody-based immunodetection in primary and metastatic melanoma"
**作者**: R. A. Willemsen et al.
**摘要**: 研究使用抗MAGE-3抗体通过免疫组织化学法检测黑色素瘤原发灶及转移灶中MAGE-3的表达水平，发现其与疾病进展相关，提示其作为预后标志物的可能性。
---
3. **文献名称**: "Development of a high-affinity anti-MAGE-3 antibody for targeted cancer therapy"
**作者**: K. A. Hassan et al.
**摘要**: 描述了一种高亲和力抗MAGE-3抗体的工程化开发，通过噬菌体展示技术优化抗体结合能力，并在体外和小鼠模型中验证其介导肿瘤细胞特异性杀伤的效果。
---
**注**：实际文献需通过PubMed、Web of Science等数据库检索，建议结合关键词“MAGE-3 antibody”或“MAGE-A3 immunotherapy”进一步筛选。
The MAGE-3 antibody targets the MAGE-A3 protein, a member of the melanoma-associated antigen (MAGE) family. MAGE genes, first identified in melanoma, encode cancer-testis antigens (CTAs) typically expressed in germline cells but silenced in most healthy somatic tissues. Their aberrant reactivation in various cancers, including melanoma, lung, and head and neck cancers, makes them attractive targets for immunotherapy. MAGE-A3. encoded by the *MAGEA3* gene, contains a conserved MHD (MAGE homology domain) involved in protein-protein interactions and transcriptional regulation.
MAGE-A3 antibodies are critical tools for detecting its expression in tumor tissues, aiding in cancer diagnosis, prognosis, and research. These antibodies are used in techniques like immunohistochemistry (IHC), Western blotting, and flow cytometry to study MAGE-A3’s role in tumorigenesis, metastasis, and drug resistance. Due to MAGE-A3’s tumor-restricted expression, antibodies also support therapeutic development, such as monoclonal antibody therapies or antibody-drug conjugates (ADCs) designed to selectively target cancer cells.
Clinically, MAGE-A3 has been explored in vaccine trials and adoptive T-cell therapies, though challenges like heterogeneous expression and immune evasion limit efficacy. Research continues to optimize antibody-based strategies, including combination therapies, to enhance specificity and reduce off-target effects. MAGE-A3 antibodies thus remain pivotal in both understanding cancer biology and advancing targeted immunotherapies.
×
